Recommendations for the treatment of infections caused by Extended-Spectrum β-lactamase producing Enterobacterales (ESBL-E), Carbapenem-resistant Enterobacterales (CRE) and Pseudomonas aeruginosa with difficult-to-treat resistance (RDR-P. aeroginosa)

Authors

  • María Garví López Area Specialist Physician. Anesthesiology, Resuscitation and Pain Therapeutics Service. University Hospital Complex of Albacete. Spain.
  • Mª LLanos Sánchez López Area Specialist Physician. Anesthesiology, Resuscitation and Pain Therapeutics Service. University Hospital Complex of Albacete. Spain.
  • Jose Mª Jiménez Vizuete Section Chief of the Anesthesia Intensive Care Unit. Anesthesiology, Resuscitation and Pain Therapeutics Service. Albacete University Hospital Complex. Spain.

DOI:

https://doi.org/10.30445/rear.v14i7.1018

Keywords:

Antimicrobial resistance, enterobacterales, Pseudomona aeruginosa, extended-spectrum β-lactamase, carbapenemase

Abstract

A group of six infectious disease experts asked a series of common questions about the treatment of infections caused by Extended Spectrum β-lactamase producing Enterobacterales (ESBL-E), Carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistances (DTR-P. aeruginosa). Based on the review of the published literature and clinical experience, a series of treatment recommendations and their rationale are provided. The recommendations apply to both adult and pediatric populations.

References

Norgaard SM, Jensen CS, Aalestrup J, Vandenbroucke-Grauls CM, De Boer MG, Pedersen AB. Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens. A systematic review. Antimicrobial Resistance and Infection Control. 2019; 8:170.

Hawkey PM, Warren RE, Livermore DM, McNulty CA, Enoch DA, Otter JA, et al. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. J Antimicrob Chemother. 2018; 73 (Suppl 3): iii2–iii78.

Aguilera-Alonso D, Escosa-García L, Goycochea-Valdivia WA, Soler-Palacín P, Saavedra-Lozano J, Rodrigo C, et al. Documento de posicionamiento de la Asociación Española de Pediatría-Sociedad Española de Infectología Pediátrica (AEP-SEIP) sobre el tratamiento de las infecciones por bacterias multirresistentes. An Pediatr. 2019; 91(5):351.e1-351.e13.

Gutiérrez-Gutiérrez B, Salamanca E, Cueto M de, Hsueh P-R, Viale P, Paño-Pardo JR, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): A retrospective cohort study. Lancet Infect Dis. 2017; 17(7): 726-34.

Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, et al. Ceftazidima-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016; 16 (6): 661-73.

Izadpanah M, Khalili H. Antibiotic regimens for treatment of infections due to multidrug-resistant gram-negative pathogens: an evidence-based literature review. J Res Pharm Pract. 2015; 4(3):105–14.

Downloads

Published

2022-08-08

How to Cite

Garví López, M., Sánchez López , M. L. ., & Jiménez Vizuete , J. M. (2022). Recommendations for the treatment of infections caused by Extended-Spectrum β-lactamase producing Enterobacterales (ESBL-E), Carbapenem-resistant Enterobacterales (CRE) and Pseudomonas aeruginosa with difficult-to-treat resistance (RDR-P. aeroginosa). Revista Electrónica AnestesiaR, 14(7). https://doi.org/10.30445/rear.v14i7.1018

Issue

Vol. 14 No. 7 (2022): Revista Electrónica de AnestesiaR

Section

Critical reviews of articles

License

Copyright (c) 2022 Revista Electrónica AnestesiaR

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Envío y derechos de autor